<DOC>
	<DOCNO>NCT02088632</DOCNO>
	<brief_summary>IncobotulinumtoxinA ( Xeomin® ) neurotoxin inhibits release certain chemical nerve terminal . It block cholinergic transmission neuromuscular junction inhibit release acetylcholine motor neuron . In addition block release Substance P ( SP ) Calcitonin Gene Related Peptide ( CGRP ) C fiber involve pain perception . This study design see Xeomin® superior placebo treatment medically refractory trigeminal neuralgia ( TN ) . Subjects ask maintain attack diary throughout study . They also ask attend 4 office visit ; Visit 1- Screening Visit , Visit 2- Injection Visit , Visit 3- Follow-Up Visit Visit 4- Final Visit . At end study active ( Xeomin® ) placebo group compare see one group well relief .</brief_summary>
	<brief_title>Botulinum Toxin Treatment Trigeminal Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Trigeminal Neuralgia</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>Inclusion Criteria Age 18 75 yr Male nonpregnant/nonlactating female Subjects must mean attack frequency least 3 episodes/day 4/10 pain Use adequate birthcontrol measure determine investigator female childbearing potential Diagnosis Classical trigeminal neuralgia ( TN ) use International Classification Headache Disorders ( ICHD2 ) criterion ( see Appendix A Protocol ) Subjects give write informed consent prior enter study Subjects stable dose concomitant preventive medication treatment TN least 4 week prior study entry throughout 12 week observation period Subjects require `` rescue '' analgesic medication study allow use current ( prestudy ) opioid and/or non opioid analgesic clinically indicate ( e.g. , nonsteroidal antiinflammatory drug ( NSAIDs ) , acetaminophen , COX2 inhibitor , topical analgesic ) . Subjects prohibit initiate therapy new preventive medication throughout remainder study . Subject must willing able abstain initiate alternative therapy ( e.g. , acupuncture , massage physical therapy ) pain relief study . ( NOTE : subject currently use alternative therapy pain relief enrol willing able maintain therapy stable throughout study . ) Exclusion Criteria Symptomatic TN Serious hepatic , respiratory , hematologic , cardiovascular renal condition Neurologic pain TN , exception occasional migraine tensiontype headache . ( &lt; 4 headache per month ; &lt; 10 headache days/month ) Psychiatric medical condition might compromise participation study , determine investigator Administration investigational drug within 30 day prior screen History substance abuse/alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>